View Clinical Trial (Medical Research Study)
The AutoloGel™ Post-Market Surveillance (TAPS) Program
| City: |
|
Augusta |
| State: |
|
Georgia |
| Zip Code: |
|
30809 |
| Conditions: |
|
Wounds - Leg Ulcers - Pressure Ulcers - Diabetic Foot Ulcers |
| Purpose: |
|
AutoloGel™ Post-Market Surveillance Program
Purpose:Evaluate the incidence of hematologic and immunologic adverse events, including
coagulopathies in patients with wounds to which AutoloGel™ was applied.
Design:Prospective, open label, patient registry. Investigator Sites: 3 Enrollment Size:
300
Subject Population: Patients with exuding wounds, such as leg ulcers, pressure ulcers, and
diabetic ulcers and for the management of mechanically or surgically-debrided wounds.
Primary Objective Safety: Assess the incidence of hematologic (coagulopathies), immunologic
(including anaphylaxis) and other adverse events associated with the application of
AutoloGel on exuding wounds, such as leg ulcers, pressure ulcers and diabetic ulcers and
during the management of mechanically or surgically-debrided wounds.
Primary Safety Endpoint: Absence of coagulopathies caused by inhibitors to coagulation
Factor V as determined by a significant prolongation of the prothrombin (PT) time and
confirmed by severe depletion of Factor V activity with a positive Bethesda Assay for
anti-Factor V functional inhibitors.
|
| Study Summary: |
|
Device Name.
The device subject to the Post-Market Surveillance (PMS) Program is the AutoloGel™ System
which has been cleared for marketing by the Food and Drug Administration (FDA) in the
application BK060007.
The AutoloGel™ System includes.
AutoloGel™ Centrifuge II AutoloGel™ System Wound Dressing and Reagent Kits including
single-use, disposable components for performing a patient phlebotomy, centrifuging blood to
derive PRP and activating and applying the AutoloGel.
The Instructions for Use include a detailed description and procedures for making AutoloGel
and a list of the Kit components which is provided at the end of the Instructions.
Indications for Use.
The AutoloGel™ System is intended to be used at point-of-care for the safe and rapid
preparation of platelet-rich plasma (PRP) gel from a small sample of a patient's own blood.
Under the supervision of a healthcare professional, the PRP gel produced by the AutoloGel™
System is suitable for exuding wounds, such as leg ulcers, pressure ulcers, and diabetic
ulcers and for the management of mechanically or surgically-debrided wounds.
Dosing.
The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a
week for eight (8) weeks. The treating health care practitioner may elect to continue the
treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with
standard of care procedures for comprehensive wound management.
Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis
ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment
Management of wound infection Wound cleansing Nutritional support, including blood glucose
control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure
ulcers at risk for contamination Management of underlying disease
Precautions and Warnings.
Caution. Federal Law (U.S.A.) restricts this device to sale by or on the order of a
Physician.
Precautions.
Throughout the processing procedure and application of AutoloGel™, use universal precautions
as defined by the facility policy and procedure manual.
All parts of the procedure shall be performed in such a manner to minimize splashing,
spraying, spattering, and generation of potential droplets.
Warnings.
AutoloGelTM is produced with the use of bovine thrombin. The use of topical bovine thrombin
preparations has occasionally been associated with abnormalities of hemostasis ranging from
asymptomatic alterations in laboratory determinations, such as prothrombin time (PT) and
partial thromboplastin time (PTT), to severe bleeding or thrombosis which have rarely been
fatal. These hemostatic effects appear to be related to the formation of antibodies against
bovine thrombin and / or factor V which in some cases may cross react with human factor V,
potentially resulting in factor V deficiency. Repeated clinical applications of topical
bovine thrombin increase the likelihood that antibodies against thrombin and / or factor V
may be formed. Consultation with an expert in coagulation disorders is recommended if a
patient exhibits abnormal coagulation laboratory values, abnormal bleeding or abnormal
thrombosis following the use of topical thrombin. Any interventions should consider the
immunologic basis of this condition. Patients with antibodies to bovine thrombin
preparations should not be re-exposed to these products.
Allergic reactions may be encountered in persons known to be sensitive to bovine materials.
Because of thrombin's action in the clotting mechanism, AutoloGel must not be injected or
otherwise allowed to enter large blood vessels. Extensive intravascular clotting and even
death may result.
|
| Criteria: |
|
Inclusion Criteria:
- A patient who meets all the following criteria will be enrolled in the postmarket
surveillance program:
- Presents with exuding wounds, such as leg ulcers, pressure ulcers, and diabetic
ulcers and mechanically or surgically-debrided wounds.
- Male or female subject of any race, and 18 to 95 years old.
Exclusion Criteria:
- Study investigator(s) shall follow the Contraindications, Precautions, and Warnings
relevant to subjects enrolled for treatment of wounds;
- Subjects will be excluded from the trial if any of the following criteria are met:
- If the Subject is on Coumadin medication (or another medication that is known to
affect a potential coagulopathy) and has an elevated PT (prothrombin time) at the
alert level at baseline, he/she will NOT be enrolled in the surveillance program.
- Ensure the patient does not have any Contraindications as noted in the AutoloGel
System Instructions for use, specifically:
- Patients known to be sensitive to components and / or materials of bovine origin
- Patients on chemotherapeutic agents
- Patients with the following abnormal laboratory test levels
- hemoglobin <10.5 g/dL
- platelet count <100 x 109/L
- serum albumin level < 2.5 g/dL
- Wounds due to malignancy
- Wounds with active clinically diagnosed infection
|
| NCT ID: |
|
NCT00762138 |
| Primary Contact: |
|
Principal Investigator
Macy G Hall, MD
Speciality Hospital of Washington - Hadley
Suzette L Arch, BA, BS
Phone: 240-499-2680
Email: sarch@cytomedix.com
|
| Backup Contact: |
|
Email: cfyling@EOT.COM
Carelyn Fyling, RN
Phone: 218-547-4142
|
| Location Contact: |
|
Augusta, Georgia 30809
United States
Elangovan Gopal, PhD
Phone: 706-868-0319
Email: adhielango@yahoo.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|